Physician profile
Mirela Andrei
NPI 1578875225
$21,946.76
in general payments reported to CMS, 2019-2025
96 companies · $4,115 in 2025
The $4,115 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $2,709 · 2021: $3,561 · 2022: $3,462 · 2023: $3,928 · 2024: $4,041 · 2025: $4,115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,944.69 |
| Education | $139.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,526.56 | 2020-2025 | Tecvayli, Darzalex, Erleada |
| Astrazeneca Pharmaceuticals Lp | $1,221.26 | 2020-2025 | Enhertu, Imfinzi |
| Pfizer INC. | $1,186.34 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,057.21 | 2019-2025 | Opdivo, Opdualag, Sprycel |
| Novartis Pharmaceuticals Corporation | $1,001.13 | 2021-2025 | |
| Amgen INC. | $995.20 | 2019-2023 | Blincyto, Kyprolis |
| Genentech USA, INC. | $970.80 | 2019-2025 | Tecentriq, Alecensa, Polivy |
| Celgene Corporation | $880.44 | 2020-2025 | Reblozyl, Sprycel |
| Merck Sharp & Dohme LLC | $723.89 | 2020-2025 | Keytruda, Welireg, Lynparza |
| Incyte Corporation | $671.24 | 2020-2025 | Jakafi, Monjuvi, Pemazyre |
| Abbvie INC. | $608.74 | 2020-2025 | Venclexta |
| Eisai INC. | $592.69 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $584.23 | 2020-2025 | Ninlaro, Alunbrig, Iclusig |
| Pharmacyclics LLC, An Abbvie Company | $524.52 | 2020-2023 | Imbruvica, Epkinly |
| Astellas Pharma US INC | $501.00 | 2020-2025 | Padcev, Cresemba, Vyloy |
Show all 96 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mirela Andrei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.